局部氟尿嘧啶乳膏对角质形成细胞癌(非黑色素瘤皮肤癌)及光化性角化病治疗费用的影响
本研究基于退伍军人事务部角质形成细胞癌化学预防试验,分析面部和耳部单疗程局部5%氟尿嘧啶(5-FU)对3年内角质形成细胞癌(KC)和光化性角化病(AK)治疗费用的影响。结果显示,随机化后1年,干预组治疗及皮肤科费用低于对照组($2106 vs $2444,P=0.02),且干预组鳞状细胞癌治疗 encounters 均值低于对照组(0.01 vs 0.04,P<.01);3年后干预组每例患者费用节省$771。作者结论为接受5-FU治疗的患者存在显著费用节省。
要点
- 面部和耳部单疗程局部5%氟尿嘧啶可降低角质形成细胞癌和光化性角化病的治疗费用。
- 随机化后1年,干预组治疗及皮肤科费用为$2106,对照组为$2444(P=0.02)。
- 3年后干预组每例患者费用较对照组节省$771。
核心结论
- 作者发现接受5-FU治疗的患者存在显著费用节省。
研究设计与样本
- 基于退伍军人事务部角质形成细胞癌化学预防试验,比较局部5%氟尿嘧啶与赋形剂对照乳膏降低KC风险的效果,并分析试验数据与行政管理费用及利用数据。
- 采用调整模型检验治疗组间治疗 encounters 数量和费用的统计学显著差异。
主要发现
- 随机化后1年,对照组鳞状细胞癌治疗 encounters 均值为0.04,高于干预组的0.01(P<.01)。
- 随机化后1年,干预组治疗及皮肤科费用为$2106(标准差$2079),低于对照组的$2444(标准差$2716)(P=0.02)。
- 3年后,干预组每例患者费用较对照组节省$771。
临床怎么用
- 原文未据此给出推荐。
局限性
- 未包含退伍军人事务部未提供或未付费的医疗照护。
- 结果可能无法推广至其他支付方。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It is unknown whether treatment costs for keratinocyte carcinoma (KC) and actinic keratosis (AK) can be lowered by spending more on chemoprevention. OBJECTIVE: To examine the impact of 1-course treatment with topical fluorouracil (5-FU) on the face and ears on KC and AK treatment costs over 3 years. METHODS: The Veterans Affairs Keratinocyte Carcinoma Chemoprevention trial compared the efficacy of topical 5-FU 5% with that of vehicle control cream for reducing KC risk. Trial data and administrative data on costs and utilization were analyzed to measure postrandomization encounters and treatment costs for KC and AK care. Adjusted models were used to test for statistically significant differences between treatment arms for number of treatment encounters and costs. RESULTS: One year after randomization, the control arm had a higher mean number of treatment encounters for squamous cell carcinoma (0.04) than the intervention arm (0.01) (P < .01). At 1 year, the intervention arm had lower treatment and dermatologic costs: $2106 (standard deviation, $2079) compared with $2444 (standard deviation, $2716) for the control patients (P = .02). After 3 years, the intervention arm incurred a cost of $771 less per patient. LIMITATIONS: Care not provided or paid for by the Department of Veterans Affairs was not included. Results may not be generalizable to other payers. CONCLUSION: We found significant cost savings for patients treated with 5-FU.
引用
- Yoon J, Phibbs CS, Chow A, et al. Impact of topical fluorouracil cream on costs of treating keratinocyte carcinoma (nonmelanoma skin cancer) and actinic keratosis. J Am Acad Dermatol. 2018. PMID: 29505863. doi:10.1016/j.jaad.2018.02.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。